Lannett Co Inc (NYSE:LCI) CEO Arthur P. Bedrosian sold 42,000 shares of the stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $25.50, for a total value of $1,071,000.00. Following the completion of the transaction, the chief executive officer now directly owns 636,616 shares in the company, valued at approximately $16,233,708. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Lannett Co Inc (NYSE LCI) traded up $1.95 during midday trading on Monday, hitting $27.50. The stock had a trading volume of 754,300 shares, compared to its average volume of 790,798. The firm has a market capitalization of $1,040.00, a price-to-earnings ratio of 10.22, a P/E/G ratio of 2.30 and a beta of 2.73. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.90 and a current ratio of 2.52. Lannett Co Inc has a 52 week low of $14.90 and a 52 week high of $27.90.
Lannett (NYSE:LCI) last released its quarterly earnings results on Monday, November 6th. The company reported $0.60 EPS for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.08. The company had revenue of $155.00 million for the quarter, compared to analyst estimates of $153.62 million. Lannett had a return on equity of 18.23% and a net margin of 6.67%. Lannett’s revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.77 earnings per share. analysts anticipate that Lannett Co Inc will post 2.99 EPS for the current fiscal year.
Several research firms have weighed in on LCI. ValuEngine raised Lannett from a “hold” rating to a “buy” rating in a research note on Saturday. Zacks Investment Research raised Lannett from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Friday, November 10th. BMO Capital Markets raised their price target on Lannett from $20.00 to $22.00 and gave the stock a “market perform” rating in a research report on Monday, November 13th. BidaskClub lowered Lannett from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Deutsche Bank AG dropped their price target on Lannett from $23.00 to $19.00 and set a “hold” rating on the stock in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $22.80.
Several large investors have recently bought and sold shares of the stock. SRS Capital Advisors Inc. grew its holdings in shares of Lannett by 15,202.7% during the third quarter. SRS Capital Advisors Inc. now owns 16,833 shares of the company’s stock worth $310,000 after buying an additional 16,723 shares in the last quarter. Neuberger Berman Group LLC bought a new position in shares of Lannett during the third quarter worth about $188,000. California Public Employees Retirement System grew its holdings in shares of Lannett by 3.9% during the third quarter. California Public Employees Retirement System now owns 81,146 shares of the company’s stock worth $1,497,000 after buying an additional 3,046 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Lannett during the third quarter worth about $700,000. Finally, Cornerstone Capital Management Holdings LLC. bought a new position in shares of Lannett during the third quarter worth about $414,000. Institutional investors and hedge funds own 96.83% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Lannett Co Inc (LCI) CEO Sells $1,071,000.00 in Stock” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://transcriptdaily.com/2017/11/27/lannett-co-inc-lci-ceo-sells-1071000-00-in-stock.html.
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.